Spring 2024 COVID-19 vaccination campaign: Pfizer BioNTech Comirnaty XBB.1.5 30 micrograms/dose mRNA vaccine: assessment
Session information
- Title:
- Spring 2024 COVID-19 vaccination campaign: Pfizer BioNTech Comirnaty XBB.1.5 30 micrograms/dose mRNA vaccine: assessment
- Description:
-
This session will present you with a series of multiple-choice questions to test your knowledge of the Pfizer-BioNTech Comirnaty XBB.1.5 30 micrograms/dose COVID-19 vaccine and its use during the spring 2024 vaccination campaign.
Once you have answered a question, please select the 'Save Answer' button. Then select the 'Next' button to move on to the next question.
You will not be able to change your answer once you have clicked on the 'submit' button. Please ensure that you finalise your answers to all the questions before submitting them for marking as you will not be able to change them once they have been submitted and marked.
Some questions require more than 1 correct answer and all of the correct options will need to be selected in order for you to get the question right. For example, if you select 2 out of 3 correct options, you will get a score of 0/3 for that question.
Once you have answered all 10 questions, you will be given the opportunity to see the correct answer to each question and feedback as to why this is the correct answer. You will also be given your final score and you will be informed if you have passed the assessment. - Hierarchy:
- Coronavirus (COVID-19) > COVID-19 Vaccination > Spring 2024 COVID-19 vaccination campaign: Pfizer BioNTech Comirnaty XBB.1.5 30 micrograms/dose mRNA vaccine: assessment > Spring 2024 COVID-19 vaccination campaign: Pfizer BioNTech Comirnaty XBB.1.5 30 micrograms/dose mRNA vaccine: assessment
- Author(s):
-
Lesley McFarlane
Michelle Falconer
Laura Craig
- Created:
- 30 Nov 2020
- Last Major Update:
- 9 Apr 2024
- Keywords:
- 099-0004, COVID, 19, coronavirus, vaccine, vaccination, immuniser, immunisation, Pfizer
- Quicklink:
- 099-0004
Share this item
- Copy URL
Overall rating
4.6/5
4.6/5
Content
4.6/5
4.6/5
Presentation
4.6/5
4.6/5
Interactivity
4.6/5
4.6/5
Self assessments
4.6/5
4.6/5
Overall rating
4.6/5
4.6/5
Content
4.6/5
4.6/5
Presentation
4.6/5
4.6/5
Interactivity
4.6/5
4.6/5
Self assessments
4.6/5
4.6/5
- Title:
- Spring 2024 COVID-19 vaccination campaign: Pfizer BioNTech Comirnaty XBB.1.5 30 micrograms/dose mRNA vaccine: assessment
- Description:
-
This session will present you with a series of multiple-choice questions to test your knowledge of the Pfizer-BioNTech Comirnaty XBB.1.5 30 micrograms/dose COVID-19 vaccine and its use during the spring 2024 vaccination campaign.
Once you have answered a question, please select the 'Save Answer' button. Then select the 'Next' button to move on to the next question.
You will not be able to change your answer once you have clicked on the 'submit' button. Please ensure that you finalise your answers to all the questions before submitting them for marking as you will not be able to change them once they have been submitted and marked.
Some questions require more than 1 correct answer and all of the correct options will need to be selected in order for you to get the question right. For example, if you select 2 out of 3 correct options, you will get a score of 0/3 for that question.
Once you have answered all 10 questions, you will be given the opportunity to see the correct answer to each question and feedback as to why this is the correct answer. You will also be given your final score and you will be informed if you have passed the assessment. - Hierarchy:
- Coronavirus (COVID-19) > COVID-19 Vaccination > Spring 2024 COVID-19 vaccination campaign: Pfizer BioNTech Comirnaty XBB.1.5 30 micrograms/dose mRNA vaccine: assessment > Spring 2024 COVID-19 vaccination campaign: Pfizer BioNTech Comirnaty XBB.1.5 30 micrograms/dose mRNA vaccine: assessment
- Author(s):
-
Lesley McFarlane
Michelle Falconer
Laura Craig
- Created:
- 30 Nov 2020
- Last Major Update:
- 9 Apr 2024
- Keywords:
- 099-0004, COVID, 19, coronavirus, vaccine, vaccination, immuniser, immunisation, Pfizer
- Quicklink:
- 099-0004